대한뉴팜

- Achieved 28.9% increase in sales and 24.4% increase in operating profit compared to the previous year

- Confirmed receipt of the 10 Million Dollar Export Tower Award

Daehan New Pharm’s growth momentum continued through the third quarter of 2015.

By the end of Q3 2015, cumulative sales reached 66.955 billion KRW, up 28.9% year-over-year, and operating profit increased by 24.4% to 7.293 billion KRW. The operating profit margin also improved to 10.9%, indicating sustained qualitative growth driven by profitability.

In addition to this growth, the company reduced accounts receivable by 353 million KRW and borrowings by 1.548 billion KRW compared to the end of 2014. This led to an improvement in accounts receivable turnover days by 33.7 days and a reduction in the debt-to-sales ratio by 11.2 percentage points to 43.5%, contributing to financial stabilization.

Daehan New Pharm’s strategy focuses on its mission to promote healthy lives, a happy society, and warmth by emphasizing fundamentals, strengthening core capabilities, prioritizing cash flow, proactive management, pioneering product launches, expanding distribution coverage through creative sales solutions, and talent-centered management, continuously driving value innovation.

The overseas business division also recorded remarkable export growth. By developing the wellness product market in China and solidifying partnerships in Russia, the company secured the 10 Million Dollar Export Tower Award.

Since beginning exports to Southeast Asia, including Vietnam, in 1999, Daehan New Pharm won the 5 Million Dollar Export Tower Award in 2007.

The company exports various pharmaceuticals, including obesity treatments, to over 30 countries worldwide such as Russia, CIS countries, Vietnam, Pakistan, and Cuba. Achieving 10 million dollars in finished pharmaceutical exports reflects the internationally recognized superior quality of its products.

This achievement affirms Daehan New Pharm’s position as a globally trusted pharmaceutical exporter.